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Abstract: AIMS The aim of this study was to investigate the effect of ticagrelor monotherapy after
one-month dual antiplatelet therapy (DAPT) or conventional DAPT in patients with or without acute
coronary syndrome (ACS) in the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). METHODS
AND RESULTS Risk estimates were expressed as rate ratios (RR) with 95% confidence intervals (CI).
A total of 3,840 ACS and 3,745 stable ischaemic heart disease (SIHD) patients were included. At two
years, rates of the co-primary efficacy endpoint, a composite of death, myocardial infarction, stroke or
urgent target vessel revascularisation, were 7.94% in the experimental and 9.68% in the control group
(RR 0.82, 95% CI: 0.66-1.01) among ACS patients and 6.31% in the experimental and 7.14% in the
control group (RR 0.89, 95% CI: 0.69-1.13) among SIHD patients (pint=0.63). Trends for lower and
higher risk of BARC 3 or 5 bleeding with the experimental strategy in ACS (2.27% vs 3.00%, RR 0.76,
95% CI: 0.51-1.12) and SIHD (2.70% vs 1.96%, RR 1.39, 95% CI: 0.91-2.12) patients, respectively, were
observed with significant interaction testing (pint=0.039). A net clinical benefit endpoint, the composite
of both co-primary study endpoints, favoured the experimental treatment among ACS patients only.
CONCLUSIONS Ticagrelor monotherapy after one-month DAPT provided consistent treatment effects
on ischaemic endpoints in patients with or without ACS but only the former experienced a net clinical
benefit. ClinicalTrials.gov identifier: NCT03231059.
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